Conference Call with Granules India Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Electrodes & Refractories company RHI Magnesita India announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from operations for Q4FY25 was Rs 917 crore PAT for Q4FY25 was Rs 36 crore FY25 Financial Highlights: Revenue from operations for FY25 was Rs 3,675 crore EBITDA for FY25 was Rs 505 crore PAT for FY25 was Rs 203 crore Net Debt/EBITDA ratio at 0.3x Commenting on the results, Parmod Sagar – Chairman, MD & CEO of RHI Magnesita India said, “Despite a challenging market environment marked by commoditization, flat shipment volumes, and lower realization rates in the refractory industry, our resilient business fundamentals enabled us to deliver the highest-ever cash flow in FY25. This was achieved even amid sustained margin pressures stemming from elevated raw material costs, which could not be fully passed on to our customers. We remain confident in our growth trajectory, driven by the continued rise in steel and cement production, along with a robust order book. Our strategic investments in the Ironmaking Excellence Center, secondary raw materials, and research & development will further enhance our cost competitiveness and strengthen our market position. I believe the recent additions to our Board with strong industry background will be a true value generation for our shareholders and our company.” Result PDF
Conference Call with Olectra Greentech Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Cement & Cement Products company Heidelberg Cement India announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Sales Volumes increased by 1.9% (1,256 KT vs 1,233 KT) Revenue grew by 2.7% (Rs 6,125 million vs Rs 5,966 million) EBITDA increased by 2.0% (Rs 906 million vs Rs 889 million) EBITDA Margin decreased by 10 basis points (14.8% vs 14.9%) Profit After Tax rose by 4.7% (Rs 504 million vs Rs 482 million) EBITDA per tonne remained almost flat with a marginal increase of 0.1% (Rs 722 vs Rs 721) FY25 Financial Highlights: Sales Volumes declined by 6.1% (4,515 KT vs 4,807 KT) Revenue declined by 9.2% (Rs 21,489 million vs Rs 23,658 million) EBITDA declined by 24.4% (Rs 2,394 million vs Rs 3,167 million) EBITDA Margin fell by 225 basis points (11.1% vs 13.4%) Profit After Tax dropped by 36.4% (Rs 1,068 million vs Rs 1,678 million) EBITDA per tonne declined by 19.5% (Rs 530 vs Rs 659) As at March 31, 2025, the cash & bank balance stood at Rs 4,536 million as against interest-free borrowings of Rs 687 million. Result PDF
Auto Parts & Equipment company Suprajit Engineering announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue increased by 4.1% (Rs 8,153 crore vs Rs 7,831 crore) EBITDA increased by 12.0% (Rs 1,057 crore vs Rs 944 crore) EBITDA Margin improved from 12.1% to 13.0% FY25 Financial Highlights: Revenue increased by 7.2% (Rs 31,056 crore vs Rs 28,959 crore) EBITDA increased by 23.1% (Rs 4,011 crore vs Rs 3,259 crore) EBITDA Margin improved from 11.3% to 12.9% Result PDF
Conference Call with JK Lakshmi Cement Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Supriya Lifescience announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: In the fourth quarter of FY25, Supriya Lifescience Ltd. witnessed remarkable growth in its revenue, reporting a 16.4 % year-over-year increase, reaching Rs 184.11 crore compared to Rs 158.18 crore in Q4FY24. EBITDA for Q4FY25 stood at Rs 67.58 crore, with an EBITDA Margin of 36.7 %, as opposed to an EBITDA of Rs 55.5 crore in Q4FY24 with an EBITDA margin of 35.1%. This marks an improvement of 162 bps YoY. Profit after Tax for Q4FY25 stood at Rs 50.38 crore, with a growth of 38.4% compared to Rs 36.40 crore in Q4FY24. The PAT Margin stood at 27.4% in Q4FY25, compared to 23.0% in Q4FY24 FY25 Financial Highlights: In FY25, Supriya Lifescience Ltd. witnessed remarkable growth in its revenue, reporting a 22% year-over-year increase, reaching Rs 696.48 crore compared to Rs 570.37 crore in FY24. EBITDA for FY25 stood at Rs 260.80 crore, with an EBITDA Margin of 37.4 %, as opposed to an EBITDA of Rs 172.98 crore in FY24 with an EBITDA margin of 30.3%. This marks an improvement of 712 bps YoY. Profit after Tax for FY25 stood at Rs 187.96 crore, with a growth of 57.8% compared to Rs 119.11 crore in FY24. The PAT Margin stood at 27.0% in FY25, compared to 20.9% in FY24. Satish Wagh, Chairman and Whole Time Director, Supriya Lifescience commenting on the results, said, “FY25 has been a landmark year for Supriya Lifescience, reflecting the strength of our diversified product portfolio, resilient global operations, and consistent focus on operational excellence. We achieved our highest-ever annual revenue of Rs 697 crore, up 22% year-on-year, and delivered an EBITDA of Rs 261 crore with a robust margin of 37.4%. In Q4FY25, revenue grew by 16.4% to Rs 184.11 crore, while PAT rose by 38.4% to Rs 50.38 crore, supported by improved margins. Our strategic focus on high-value therapeutic segments, deeper penetration in regulated markets, and strengthened backward integration continue to drive our performance. We remain committed to building on this momentum to deliver sustainable growth, foster innovation, and create long-term value for all stakeholders.” Result PDF